Cantor Fitzgerald sets $20 price target for Core Scientific stock: Should you buy?
Core Scientific Inc (NASDAQ: CORZ) has recently been garnering a lot of attention from financial analysts. On Wednesday, Cantor Fitzgerald initiated coverage of the company, assigning an “overweight” rating with a compelling $20.00 price target.
This suggests a substantial upside of nearly 71% from the current stock price, signaling strong confidence in the company’s future prospects.
Concurrently, today B. Riley Securities upgraded their rating on Core Scientific from Neutral to Buy, driven by the company’s strategic expansion into high-performance computing (HPC) hosting.
The upgrade by B. Riley Securities stems from Core Scientific’s recent deals, particularly with CoreWeave. Analyst Lucas Pipes highlighted the company’s potential to become a leader in the HPC space.
This optimism is supported by a series of long-term contracts with CoreWeave, expected to generate over $3.5 billion in revenue across the next 12 years.
These contracts not only signify a robust revenue stream but also mark a strategic pivot towards leveraging Core Scientific’s extensive infrastructure for AI data centers—a growing industry demand.
Bernstein analyst Gautam Chhugani also provided a positive outlook on July 10th, starting coverage of Core Scientific with an “Outperform” rating.
Chhugani emphasized the company’s ideal setup for AI data center collaboration due to its power infrastructure and operational capabilities.
He anticipates a significant portion of the company’s power capacity, about 20%, transitioning to support AI by 2027, reinforcing the strategic shift towards diversified high-value compute services.
Financial performance and business challenges
Core Scientific’s financial results underscores these strategic advancements. The company reported a GAAP EPS of $0.78 for Q1 2024, with revenue reaching $179.29 million, marking a 48.6% increase year-over-year.
This robust financial performance is rooted in both its traditional bitcoin mining operations and its burgeoning HPC services, with a net income of $210.7 million highlighting operational efficiency and profitability.
However, Core Scientific’s journey has seen its challenges. Despite the strategic expansions, the company faced a momentary dip when it updated its June production figures, showing a decrease in bitcoin mined compared to the previous month.
Yet, this was quickly overshadowed by the overall positive momentum driven by analyst upgrades and operational successes.
CoreWeave’s bid
In a notable event earlier in June, Core Scientific rejected an unsolicited proposal from CoreWeave to acquire the company at $5.75 per share, which it considered undervalued.
This proposal came shortly after Core Scientific disclosed the lucrative 12-year contracts with CoreWeave, indicating significant external interest and perceived value in Core Scientific’s operational and strategic direction.
This series of developments—from analyst upgrades, strategic pivots towards HPC hosting, to handling unsolicited acquisition offers—positions Core Scientific positively in the eyes of investors.
With all these facets considered, Core Scientific represents a multifaceted investment opportunity, poised for potential growth in both its established and emerging business areas.
Now, as we turn toward the technical analysis, we will assess how these fundamental strengths and strategic initiatives are reflected in Core Scientific’s stock price movements and what the charts might indicate about its future trajectory.
Super strong short-term momentum
In January this year, Core Scientific emerged from bankruptcy, completed its reorganization process and relisted its shares on the Nasdaq.
The stock entered a bullish phase in May this year when it was trading below $3.
Following the bid from CoreWeave, the stock skyrocketed in June and that strong rally has resulted in it appreciating more than 400% from its April lows.
The stock continues to enjoy strong bullish momentum hence short-term traders must refrain from shorting it currently.
Investors who are bullish on the company’s prospects and are looking to enter long positions must try to accumulate it at levels below $11 with a stop loss at $8.9, which has been acting as a strong support since late June.
If the bullish momentum continues, the stock might reach the price target assigned by Cantor Fitzgerald in the coming months.
The post Cantor Fitzgerald sets $20 price target for Core Scientific stock: Should you buy? appeared first on Invezz
